$3.96
-0.22 (-5.26%)
Open$4.18
Previous Close$4.18
Day High$4.18
Day Low$3.91
52W High$7.75
52W Low$3.94
Volume—
Avg Volume154.0K
Market Cap98.05M
P/E Ratio—
EPS$-1.27
SectorBiotechnology
Analyst Ratings
Strong Buy
13 analysts
Price Target
+830.6% upside
Current
$3.96
$3.96
Target
$36.85
$36.85
$27.29
$36.85 avg
$45.13
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 11.03M | 21.48M | 20.04M |
| Net Income | -29,478,041 | -5,165,355 | -3,853,498 |
| Profit Margin | -267.1% | -24.1% | -19.2% |
| EBITDA | -29,436,218 | -6,655,427 | -5,995,002 |
| Free Cash Flow | — | -3,535,951 | -2,421,928 |
| Rev Growth | — | -8.7% | +0.8% |
| Debt/Equity | — | 0.24 | 0.25 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $214.98 | -1.15% | 166.6 | 397.77B |
| AMGN | Amgen Inc | $353.28 | +0.41% | 24.7 | 190.40B |
| GILD | Gilead Sciences Inc | $140.30 | +0.67% | 19.6 | 166.66B |
| VRTX | Vertex Pharmaceuticals Inc | $447.26 | +0.16% | 29.1 | 114.87B |
| REGN | Regeneron Pharmaceuticals | $777.25 | +0.60% | 17.9 | 80.50B |
| ALNY | Alnylam Pharmaceuticals Inc | $328.73 | -0.65% | 139.7 | 43.84B |